HDAC2 and prostate cancer: Furthermore, silibinin caused a modest, concentration-dependent increase in overall DNA methyltransferase activity, a decrease in HDAC1 and HDAC2 expression levels, and was associated with EMT and cancer stem cell phenotypes in prostate cancer [156].